We propose that clinical targeting of CCN1 may be beneficial in reducing tumor growth, invasion, and angiogenesis, and we demonstrate that targeting CCN1 in the vasculature, which is easily accessible to therapeutics, could also prevent cancer intravasation and subsequent metastasis. Here, CCN1 is linked to neoplasm.